Junshi Biosciences Announces NMPA Accepted supplemental New Drug Application for Toripalimab in Combination with Chemotherapy as First-Line Treatment of Advanced NSCLC
The study enrolled 465 NSCLC patients in 63 centers in China, among which 220 were squamous NSCLC patients and 245 were non-squamous NSCLC patients.
- The study enrolled 465 NSCLC patients in 63 centers in China, among which 220 were squamous NSCLC patients and 245 were non-squamous NSCLC patients.
- Existing domestic and overseas studies have shown that monotherapy or combination chemotherapy of anti-PD-(L)1 monoclonal antibody has already become new standard for the first-line treatment of NSCLC.
- Coherus and Junshi Biosciences plan to file additional toripalimab BLAs with the FDA over the next three years for multiple other cancer types.
- Junshi Biosciences has over 2,500 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing and Guangzhou).